Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selcuk Ecza Deposu Ticaret venayi AS (IST:SELEC) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Selcuk Ecza Deposu Ticaret venayi AS's Enterprise Value for the quarter that ended in Mar. 2026 was ₺44,734 Mil.
Selcuk Ecza Deposu Ticaret venayi AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺4,282 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Selcuk Ecza Deposu Ticaret venayi AS EV-to-EBIT Related Terms
Selcuk Ecza Deposu Ticaret venayi AS EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Selcuk Ecza Deposu Ticaret venayi AS EV-to-EBIT Chart
For the Medical Distribution subindustry, Selcuk Ecza Deposu Ticaret venayi AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Selcuk Ecza Deposu Ticaret venayi AS EV-to-EBIT vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Selcuk Ecza Deposu Ticaret venayi AS's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Selcuk Ecza Deposu Ticaret venayi AS's EV-to-EBIT falls into.
Selcuk Ecza Deposu Ticaret venayi AS's current Enterprise Value is ₺141,113 Mil.
Selcuk Ecza Deposu Ticaret venayi AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺4,282 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Selcuk Ecza Deposu Ticaret venayi AS (IST:SELEC) has a EV-to-EBIT of 32.96 as of Jul. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Selcuk Ecza Deposu Ticaret venayi AS and its competitors. This is 455% above median its historical median of 5.94. Over the past decade, Selcuk Ecza Deposu Ticaret venayi AS's EV-to-EBIT has ranged from 2.61 to 42.47. According to the industry distribution chart, Selcuk Ecza Deposu Ticaret venayi AS ranks #87 out of 94 companies in the Medical Distribution industry, placing it in the top 92.6%.
Is Selcuk Ecza Deposu Ticaret venayi AS's EV-to-EBIT too high?
Selcuk Ecza Deposu Ticaret venayi AS's current EV-to-EBIT of 32.96 is 455% above median its 10-year median of 5.94. Over the past 10 years, this metric has ranged from a low of 2.61 to a high of 42.47. The Medical Distribution industry median EV-to-EBIT is 11.53. Selcuk Ecza Deposu Ticaret venayi AS's value of 32.96 is 185.9% above this industry median. Based on the distribution chart, Selcuk Ecza Deposu Ticaret venayi AS ranks #87 out of 94 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Selcuk Ecza Deposu Ticaret venayi AS has a GF Score™ of 79/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Selcuk Ecza Deposu Ticaret venayi AS's EV-to-EBIT compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Selcuk Ecza Deposu Ticaret venayi AS ranks #87 out of 94 companies for EV-to-EBIT. This places Selcuk Ecza Deposu Ticaret venayi AS in the lower half of its industry. The industry median EV-to-EBIT is 11.53. Selcuk Ecza Deposu Ticaret venayi AS's value of 32.96 is 185.9% above this benchmark. Historically, Selcuk Ecza Deposu Ticaret venayi AS's own EV-to-EBIT has ranged from 2.61 to 42.47 over the past decade. While the company's 10-year median is 5.94 vs. the industry median of 11.53, Selcuk Ecza Deposu Ticaret venayi AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Distribution company?
The median EV-to-EBIT among Medical Distribution companies is 11.53, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Selcuk Ecza Deposu Ticaret venayi AS's current EV-to-EBIT of 32.96 is 185.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Selcuk Ecza Deposu Ticaret venayi AS and its competitors. For the Medical Distribution industry, the median EV-to-EBIT is 11.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Selcuk Ecza Deposu Ticaret venayi AS's current EV-to-EBIT is 32.96, which is 455% above median its own 10-year median of 5.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Selcuk Ecza Deposu Ticaret venayi AS stock overvalued right now?
Based on GuruFocus' analysis, Selcuk Ecza Deposu Ticaret venayi AS (IST:SELEC) is currently considered Significantly Overvalued. The stock's GF Value™ is ₺89.82, compared to a current price of ₺235.70 — trading 162.4% above its estimated fair value. The current EV-to-EBIT is 32.96, which is 455% above median its 10-year median of 5.94 and 185.9% above the Medical Distribution industry median of 11.53. Selcuk Ecza Deposu Ticaret venayi AS's overall GF Score™ is 79/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Selcuk Ecza Deposu Ticaret venayi AS (IST:SELEC), the current EV-to-EBIT is 32.96 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Selcuk Ecza Deposu Ticaret venayi AS (IST:SELEC) Overvalued in 2026?
Based on GuruFocus' analysis, Selcuk Ecza Deposu Ticaret venayi AS stock appears to be overvalued.
The current stock price of ₺235.70 is trading 162.4% above its estimated GF Value™ of ₺89.82.
GuruFocus considers Selcuk Ecza Deposu Ticaret venayi AS to be Significantly Overvalued.
Key valuation signals for IST:SELEC:
EV-to-EBIT: 32.96 (455% above median its 10-year median of 5.94)
GF Value™: ₺89.82 vs. price of ₺235.70 (162.4% above fair value)
Industry Position: 185.9% above the Medical Distribution median (#87 of 94)
No single metric tells the full story. See the IST:SELEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Selcuk Ecza Deposu Ticaret venayi AS Business Description
Selcuk Ecza Deposu Ticaret ve Sanayi AS and its subsidiaries are in the business of export and import of drugs and patent medicines, medical supplies with pharmacy depot operations and also organize distribution channels between drug manufacturers, hospitals, and pharmacies. The company also distributes cosmetics, personal care, infant food, vitamins, medical and similar products.
79GF Score
Get the complete analysis for IST:SELEC
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:SELEC has been successfully added to your 
